Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEET URO 12
2024-519519-32-00Phase 2Authorised
- Sponsor
- University of Turin
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in transitional cell carcinoma (TCC) comparing Niraparib maintenance with Best supportive care (2 arms). Primary endpoint: Progression-free survival. Planned start Jan 2025; status: authorised.
02
Drugs
niraparib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-519519-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519519-32-00.